Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Bausch & Lomb's selling, general, & admin. expense for the
three
months ended in Jun. 2026 was C$825 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2026 was C$3,080 Mil.
Bausch & Lomb (TSX:BLCO) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Bausch & Lomb Selling, General, & Admin. Expense Related Terms
Bausch & Lomb Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for Bausch & Lomb's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch & Lomb Selling, General, & Admin. Expense Chart
TSX:BLCO vs ISRG, BDX, MDLN: Selling, General, & Admin. Expense Comparison
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb Selling, General, & Admin. Expense vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's Selling, General, & Admin. Expense falls into.
Bausch & Lomb Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$3,080 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of C$3,080 Mil mean?
Bausch & Lomb (TSX:BLCO) has a Selling, General, & Admin. Expense of C$3,080 Mil as of Jun. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Bausch & Lomb and its competitors.
Is Bausch & Lomb's Selling, General, & Admin. Expense too high?
Bausch & Lomb's current Selling, General, & Admin. Expense is C$3,080 Mil. Overall, Bausch & Lomb has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bausch & Lomb's Selling, General, & Admin. Expense compare to ISRG and BDX?
Bausch & Lomb's Selling, General, & Admin. Expense of C$3,080 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Medical Devices & Instruments company?
A good Selling, General, & Admin. Expense depends on the Medical Devices & Instruments industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Bausch & Lomb and its competitors. Bausch & Lomb's current Selling, General, & Admin. Expense is C$3,080 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch & Lomb stock overvalued right now?
Based on GuruFocus' analysis, Bausch & Lomb (TSX:BLCO) is currently considered Fairly Valued. The stock's GF Value™ is C$25.43, compared to a current price of C$23.27 — trading 8.5% below its estimated fair value. The current Selling, General, & Admin. Expense is C$3,080 Mil. Bausch & Lomb's overall GF Score™ is 76/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Bausch & Lomb (TSX:BLCO), the current Selling, General, & Admin. Expense is C$3,080 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch & Lomb (TSX:BLCO) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued.
The current stock price of C$23.27 is trading 8.5% below its estimated GF Value™ of C$25.43.
GuruFocus considers Bausch & Lomb to be Fairly Valued.
Key valuation signals for TSX:BLCO:
Selling, General, & Admin. Expense: C$3,080 Mil
GF Value™: C$25.43 vs. price of C$23.27 (8.5% below fair value)
No single metric tells the full story. See the TSX:BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
76GF Score
Get the complete analysis for TSX:BLCO
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:BLCO has been successfully added to your 
